CIRC (01763) has announced that, based on a preliminary review of the Group's unaudited consolidated management accounts and currently available data for the year ending December 31, 2025, the following results are anticipated compared to the same period in 2024. Revenue is expected to be approximately RMB6.979 billion to RMB7.206 billion, representing a decrease of about 5% to 8%. Net profit is projected to be in the range of RMB611 million to RMB655 million, a reduction of approximately 25% to 30%. Profit attributable to the company's equity shareholders for the year is estimated to be between RMB302 million and RMB322 million, indicating a year-on-year decline of about 20% to 25%. The company's operations remain normal up to the present date. The decrease in revenue for the 2025 fiscal year is primarily attributed to a decline in revenue from the Group's nuclear medical equipment segment. The reduction in profit is mainly due to the impact of back taxes and late payment penalties settled by the company's subsidiary, Shenzhen Zhonghe Haidewei Biotechnology Co., Ltd.